Centre's conflicting signals on plasma therapy

A guidance doc issued on June 25 had cautioned against the use of plasma therapy but on June 27, in the revised treatment protocol, ministry endorsed off-label use of convalescent plasma.

Published: 01st July 2020 08:35 AM  |   Last Updated: 01st July 2020 08:35 AM   |  A+A-

Plasma therapy

For representational purposes

Express News Service

NEW DELHI: Even as there is no clarity on whether plasma therapy is helping moderately to severely ill Covid-19 patients, the Centre seems to be unsure about whether to allow hospitals its unbridled use and is sending contradicting signals. Just two days before permitting the therapy as an investigational treatment, even outside clinical trials, a guidance document on blood transfusion issued on June 25 had cautioned against the use of plasma therapy as routine treatment.

The guidelines made public on Tuesday clearly said the effectiveness of convalescent plasma therapy for Covid-19 is being assessed through clinical trials and has not been established yet. Therefore it should not be used for routine treatment.

“The use of convalescent plasma for routine treatment of Covid-19 patients is not recommended at present,” said the guidelines by the National Blood Transfusion Council under Union Ministry of Health and Family Welfare. Systems should be in place to enable re-entry of cured Covid-19 patients as plasma donors for treatment of Covid patients, it added.

In contrast, on June 27, in the revised treatment protocol for the infectious disease, the ministry endorsed off-label use of convalescent plasma saying it “may be considered in patients with moderate disease who are not improving (oxygen requirement is progressively increasing) despite use of steroids”. The protocol had mentioned special prerequisites while considering convalescent plasma that included ABO compatibility, monitoring of recipients following the transfusion among others. In late April, the ministry and ICMR had warned against the indiscriminate use of plasma therapy.

Queries sent out to senior officials of ministry, including health secretary Preeti Sudan, seeking clarification on the government view on plasma therapy has remained unanswered but the conflicting stand by the ministry on the issue has left patient rights groups perplexed. Despite being an experimental therapy without any proven efficacy so far, hospitals — mostly private — are charging patients heavily for it.

In Delhi, for instance, a major corporate hospital has been billing infected patients Rs 11,000 per cycle of transfusion even though it’s the families of patients who have to arrange for donors. Clinical trials of plasma therapy for Covid-19 are on in various hospitals in the country, but so far no conclusive results have come. A small randomised clinical trial from Wuhan in China had shown that among patients with severe or life-threatening Covid-19, convalescent plasma added to standard treatment when compared to non-intervention group showed marginal improvement within 28 days.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp